Zai Lab's commercialization and licensing model in China has seen multiple products included in the national reimbursement drug list (NRDL), with high visibility for revenue growth in 2026.
JD Health, a leader in internet healthcare, continues to see growth in monthly active users and online penetration of prescription drugs. Improved consumer sentiment post-ceasefire is beneficial for platform transaction volume.
Insilico Medicine is a globally representative company in AI-driven drug discovery, with pipeline progress being a short-term catalyst. Its latest funding round valued the company at over $600 million, and it is currently in a window of valuation re-rating as it transitions from an AI tool provider to a clinical-stage pipeline company.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
